AbelZeta Pharma

Focus: AbelZeta Pharma is a Shanghai-based cell therapy company focused on CAR-T cells, TCR-engineered T cells, and mesenchymal stem cell therapies across oncology and autoimmune indications. The company operates as a clinical-stage biotech with a broad pipeline but limited public financial visibility.

Gene Therapy Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About AbelZeta Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow AbelZeta Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

38 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

C-CAR011

Acute Lymphoblastic Leukemia(ALL)

N/A

Clinical Trials (1)

NCT03327285C-CAR011 Treatment in Subjects With ALL After HSCT

N/A

Help build intelligence for AbelZeta Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Broad pipeline of 19 programs across multiple cell therapy modalities (CAR-T, TCR-T, MSC exosomes) with 19 Phase 1 and 9 Phase 2 trials underway.
Leading position in China's cell therapy market with access to a rapidly expanding oncology and autoimmune patient base.
Exposure to cutting-edge immunotherapy platforms including dual-targeted CAR-T (CD20/BCMA) and novel targets (GPC3, STEAP2) with differentiation potential.

Watch Out For

No Phase 3 programs in pipeline and no marketed products—zero near-term revenue visibility or regulatory validation; career progression tied entirely to pre-clinical/early-clinical success.
Minimal published data (0 publications tracked), zero active job openings, and limited transparency on funding, headcount, and company financials create uncertainty around stability and growth trajectory.
Early-stage pipeline with many single-trial programs and no clear clinical catalysts in near term; CAR-T space highly competitive with established players (Novartis, Gilead, Juno) in same indications.

Generated by Claude from AbelZeta Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CD20-directed CAR-T cells

B Cell Lymphoma

Phase 1

Clinical Trials (1)

NCT04036019A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

Phase 1

AFP Specific T Cell Receptor T Cells

Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT03971747AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

Phase 1

Mesenchymal stem cell exosomes

Healthy Volunteers

Phase 1

CD117-directed CAR-T cells

Acute Myeloid Leukemia

Phase 1

Tumor infiltrating lymphocytes

Cervical Cancer

Phase 1

Clinical Trials (1)

NCT05475847Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer

Phase 1

Autologous T cells-based immunotherapy

Gastric Cancer

Phase 1

Clinical Trials (1)

NCT02704299The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.

Phase 1

STEAP2-targeted CAR-T cells

Metastatic Castration-Resistant Prostate Cancer

Phase 1

1X level of MSCs-Exo

Healthy

Phase 1

Clinical Trials (1)

NCT04313647A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers

Phase 1

C-CAR011

Refractory or Relapsed Non-Hodgkin Lymphoma

Phase 1

Clinical Trials (1)

NCT03154775Study of Safety and Efficacy of C-CAR011 in B-NHL Patients

Phase 1

C-CAR-011

Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1

Clinical Trials (1)

NCT03018093A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL

Phase 1

C-CAR031

Squamous Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT07444281An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer

Phase 1

dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection

Prostate Cancer

Phase 1

Clinical Trials (1)

NCT07344311A Phase I Trial of A-CAR032 in Participants With mCRPC

Phase 1

C-CAR-011

Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Clinical Trials (1)

NCT02976857A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects

Phase 1

A-CAR028

Acute Myeloid Leukemia (AML)

Phase 1

Clinical Trials (1)

NCT07198867A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

C-CAR011

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

Phase 1

Clinical Trials (1)

NCT03299738A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL

Phase 1

C-CAR066

Diffuse Large B Cell Lymphoma

Phase 1

Clinical Trials (1)

NCT04316624A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

Phase 1

MSCs-derived exosomes

Coronavirus

Phase 1

Clinical Trials (1)

NCT04276987A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia

Phase 1

CD19-directed CAR-T cells

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

Phase 1

Clinical Trials (1)

NCT03483688A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

Phase 1

Mesenchymal stem cell exosomes

Coronavirus

Phase 1/2

B-cell maturation antigen

Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT05521802A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2

BCMA-directed CAR-T cells

Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT04295018A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Phase 1

Prizloncabtagene autoleucel

Non-Hodgkin's B-cell Lymphoma

Phase 1/2

Clinical Trials (5)

NCT05800977A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Phase 1/2

NCT04317885A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

Phase 1

NCT04693676A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

Phase 1

+2 more

CD20/BCMA-directed CAR-T cells

Systemic Lupus Erythematosus

Phase 1/2

Clinical Trials (2)

NCT07341828A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy

Phase 1

NCT06249438A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Phase 1

Mesenchymal stem cells low-dose group

Knee Osteoarthritis

Phase 1/2

Clinical Trials (1)

NCT01809769Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis

Phase 1/2

Armored and GPC3-targeted autologous CAR T-cell

Hepatocellular Carcinoma

Phase 1/2

Clinical Trials (1)

NCT06590246A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)

Phase 1/2

Mesenchymal stem cell exosomes

Alzheimer Disease

Phase 1/2

Clinical Trials (1)

NCT04602104A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS

Phase 1/2

C-CAR168

Lupus Nephritis (LN)

Phase 1/2

Clinical Trials (1)

NCT06935474C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

Phase 1/2

GPC3-targeted CAR-T cells

Squamous Cell Lung Cancer

Phase 1/2

low dosage MSCs-Exos administrated for nasal drip

Alzheimer Disease

Phase 1/2

Clinical Trials (1)

NCT04388982the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease

Phase 1/2

Autologous hematopoietic stem cell transplantation

Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT05632380ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

Phase 1/2

Mesenchymal progenitor cell exosomes

Pulmonary Infection

Phase 1/2

Clinical Trials (1)

NCT04544215A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection

Phase 1/2

Autologous immune cell therapy

Metastatic Castration-resistant Prostate Cancer

Phase 1/2

Clinical Trials (2)

NCT03085966Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Phase 1/2

NCT01828762Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy

N/A

Mesenchymal progenitor cells

Knee Osteoarthritis

Phase 2

Clinical Trials (3)

NCT02162693Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis

Phase 2

NCT04208646Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis

Phase 2

NCT02641860Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis

Phase 1

Autologous adipose tissue-derived cells

Knee Osteoarthritis

Phase 2

ReJoinTM

Defect of Articular Cartilage

Phase 2

Clinical Trials (1)

NCT02855073Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects

Phase 2

Dendritic cell-T cell therapy

Hepatocellular Carcinoma

Phase N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 38 clinical trials

Top TAs: Oncology, Immunology, Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

25 pipeline

3 pipeline

3 pipeline

2 pipeline

1 pipeline

Marketed

Pipeline